{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:35:16Z","timestamp":1794897316556,"version":"4.9.1"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2025-I2M-XHCL-038"],"award-info":[{"award-number":["2025-I2M-XHCL-038"]}]},{"name":"Beijing High-Level Innovation and Entrepreneurship Talent Support Program-Healthcare Platform leading talent projects","award":["G202512005"],"award-info":[{"award-number":["G202512005"]}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-005"],"award-info":[{"award-number":["2022-PUMCH-D-005"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370179"],"award-info":[{"award-number":["82370179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02648-z","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:34:12Z","timestamp":1774496052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies"],"prefix":"10.1186","volume":"25","author":[{"given":"Weitong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2648_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","author":"G Escobar","year":"2025","unstructured":"Escobar G, Berger TR, Maus MV. Car-T cells in solid tumors: challenges and breakthroughs. Cell Rep Med. 2025. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102353.","journal-title":"Cell Rep Med"},{"key":"2648_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-025-01737-8","volume":"18","author":"N Jiang","year":"2025","unstructured":"Jiang N, Yang Z, Miao H, Xing S, Wang S, Li N. Recent advances in universal chimeric antigen receptor T cell therapy. J Hematol Oncol. 2025;18:82. https:\/\/doi.org\/10.1186\/s13045-025-01737-8.","journal-title":"J Hematol Oncol"},{"key":"2648_CR3","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153.","journal-title":"Front Immunol"},{"key":"2648_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","volume":"15","author":"S Caruso","year":"2022","unstructured":"Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;15:163. https:\/\/doi.org\/10.1186\/s13045-022-01376-3.","journal-title":"J Hematol Oncol"},{"key":"2648_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s0065-2776(08)60664-1","volume":"47","author":"G Trinchieri","year":"1989","unstructured":"Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187\u2013376. https:\/\/doi.org\/10.1016\/s0065-2776(08)60664-1.","journal-title":"Adv Immunol"},{"key":"2648_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225\u201374. https:\/\/doi.org\/10.1146\/annurev.immunol.23.021704.115526.","journal-title":"Annu Rev Immunol"},{"key":"2648_CR7","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1016\/j.ymthe.2024.01.027","volume":"32","author":"K Wang","year":"2024","unstructured":"Wang K, Wang L, Wang Y, Xiao L, Wei J, Hu Y, et al. Reprogramming natural killer cells for cancer therapy. Mol Ther. 2024;32:2835\u201355. https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.027.","journal-title":"Mol Ther"},{"key":"2648_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/cmi.2014.91","volume":"12","author":"C Sun","year":"2015","unstructured":"Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol. 2015;12:292\u2013302. https:\/\/doi.org\/10.1038\/cmi.2014.91.","journal-title":"Cell Mol Immunol"},{"key":"2648_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","volume":"121","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Wallace DL, de Lara CM, Ghattas H, Asquith B, Worth A, et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology. 2007;121:258\u201365. https:\/\/doi.org\/10.1111\/j.1365-2567.2007.02573.x.","journal-title":"Immunology"},{"key":"2648_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3390\/cancers11060769","volume":"11","author":"KB Lupo","year":"2019","unstructured":"Lupo KB, Matosevic S. Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers (Basel). 2019;11:769. https:\/\/doi.org\/10.3390\/cancers11060769.","journal-title":"Cancers (Basel)"},{"key":"2648_CR11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","volume":"114","author":"A Biederst\u00e4dt","year":"2021","unstructured":"Biederst\u00e4dt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. 2021;114:554\u201371. https:\/\/doi.org\/10.1007\/s12185-021-03209-4.","journal-title":"Int J Hematol"},{"key":"2648_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/jnci\/djz017","volume":"111","author":"BD Hunter","year":"2019","unstructured":"Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;111:646\u201354. https:\/\/doi.org\/10.1093\/jnci\/djz017.","journal-title":"J Natl Cancer Inst"},{"key":"2648_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"key":"2648_CR14","doi-asserted-by":"publisher","first-page":"e28147","DOI":"10.4161\/onci.28147","volume":"3","author":"H Klingemann","year":"2014","unstructured":"Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014;3:e28147. https:\/\/doi.org\/10.4161\/onci.28147.","journal-title":"Oncoimmunology"},{"key":"2648_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200\u201318. https:\/\/doi.org\/10.1038\/s41573-019-0052-1.","journal-title":"Nat Rev Drug Discov"},{"key":"2648_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41:119. https:\/\/doi.org\/10.1186\/s13046-022-02327-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"2648_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","volume":"6","author":"M Carlsten","year":"2015","unstructured":"Carlsten M, Childs RW. Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol. 2015;6:266. https:\/\/doi.org\/10.3389\/fimmu.2015.00266.","journal-title":"Front Immunol"},{"key":"2648_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73. https:\/\/doi.org\/10.1186\/s13045-021-01083-5.","journal-title":"J Hematol Oncol"},{"key":"2648_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","volume":"106","author":"C Imai","year":"2005","unstructured":"Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106:376\u201383. https:\/\/doi.org\/10.1182\/blood-2004-12-4797.","journal-title":"Blood"},{"key":"2648_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12967-016-1047-x","volume":"14","author":"JE Vargas","year":"2016","unstructured":"Vargas JE, Chicaybam L, Stein RT, Tanuri A, Delgado-Ca\u00f1edo A, Bonamino MH. Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives. J Transl Med. 2016;14:288. https:\/\/doi.org\/10.1186\/s12967-016-1047-x.","journal-title":"J Transl Med"},{"key":"2648_CR21","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132\u201342. https:\/\/doi.org\/10.1172\/JCI35700.","journal-title":"J Clin Invest"},{"key":"2648_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/gt.2012.88","volume":"20","author":"C Papayannakos","year":"2013","unstructured":"Papayannakos C, Daniel R. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy. Gene Ther. 2013;20:581\u20138. https:\/\/doi.org\/10.1038\/gt.2012.88.","journal-title":"Gene Ther"},{"key":"2648_CR23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nri2635","volume":"9","author":"CH June","year":"2009","unstructured":"June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol. 2009;9:704\u201316. https:\/\/doi.org\/10.1038\/nri2635.","journal-title":"Nat Rev Immunol"},{"key":"2648_CR24","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3109\/10428194.2011.634048","volume":"53","author":"L Boissel","year":"2012","unstructured":"Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma. 2012;53:958\u201365. https:\/\/doi.org\/10.3109\/10428194.2011.634048.","journal-title":"Leuk Lymphoma"},{"key":"2648_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Saleh MM, Rahman HS, Suksatan W, Al-Gazally ME, Abdelbasset WK, et al. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Res Ther. 2021;12:374. https:\/\/doi.org\/10.1186\/s13287-021-02462-y.","journal-title":"Stem Cell Res Ther"},{"key":"2648_CR26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12951-024-02746-4","volume":"22","author":"EM McErlean","year":"2024","unstructured":"McErlean EM, McCarthy HO. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery. J Nanobiotechnology. 2024;22:552. https:\/\/doi.org\/10.1186\/s12951-024-02746-4.","journal-title":"J Nanobiotechnology"},{"key":"2648_CR27","doi-asserted-by":"publisher","first-page":"13364","DOI":"10.3390\/ijms241713364","volume":"24","author":"V Golubovskaya","year":"2023","unstructured":"Golubovskaya V, Sienkiewicz J, Sun J, Zhang S, Huang Y, Zhou H, et al. CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo. Int J Mol Sci. 2023;24:13364. https:\/\/doi.org\/10.3390\/ijms241713364.","journal-title":"Int J Mol Sci"},{"key":"2648_CR28","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1093\/nar\/gks643","volume":"40","author":"M Rostovskaya","year":"2012","unstructured":"Rostovskaya M, Fu J, Obst M, Baer I, Weidlich S, Wang H, et al. Transposon-mediated BAC transgenesis in human ES cells. Nucleic Acids Res. 2012;40:e150. https:\/\/doi.org\/10.1093\/nar\/gks643.","journal-title":"Nucleic Acids Res"},{"key":"2648_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-018-0441-8","volume":"6","author":"J Wang","year":"2018","unstructured":"Wang J, Lupo KB, Chambers AM, Matosevic S. Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. J Immunother Cancer. 2018;6:136. https:\/\/doi.org\/10.1186\/s40425-018-0441-8.","journal-title":"J Immunother Cancer"},{"key":"2648_CR30","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1182\/blood-2021-153999","volume":"138","author":"T Bexte","year":"2021","unstructured":"Bexte T, Botezatu L, Miskey C, Campe J, Reindl LM, Gebel V, et al. Non-viral sleeping beauty transposon engineered CD19-CAR-NK cells show a safe genomic integration profile and high antileukemic efficiency. Blood. 2021;138:2797\u20132797. https:\/\/doi.org\/10.1182\/blood-2021-153999.","journal-title":"Blood"},{"key":"2648_CR31","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.ymthe.2024.04.024","volume":"32","author":"JG Skeate","year":"2024","unstructured":"Skeate JG, Pomeroy EJ, Slipek NJ, Jones BJ, Wick BJ, Chang JW, et al. Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies. Mol Ther. 2024;32:1817\u201334. https:\/\/doi.org\/10.1016\/j.ymthe.2024.04.024.","journal-title":"Mol Ther"},{"key":"2648_CR32","doi-asserted-by":"publisher","first-page":"1414264","DOI":"10.3389\/fimmu.2024.1414264","volume":"15","author":"R Yang","year":"2024","unstructured":"Yang R, Yang Y, Liu R, Wang Y, Yang R, He A. Advances in CAR-NK cell therapy for hematological malignancies. Front Immunol. 2024;15:1414264. https:\/\/doi.org\/10.3389\/fimmu.2024.1414264.","journal-title":"Front Immunol"},{"key":"2648_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","volume":"28","author":"EJ Pomeroy","year":"2020","unstructured":"Pomeroy EJ, Hunzeker JT, Kluesner MG, Lahr WS, Smeester BA, Crosby MR, et al. A genetically engineered primary human natural killer cell platform for cancer immunotherapy. Mol Ther. 2020;28:52\u201363. https:\/\/doi.org\/10.1016\/j.ymthe.2019.10.009.","journal-title":"Mol Ther"},{"key":"2648_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","volume":"126","author":"A Poli","year":"2009","unstructured":"Poli A, Michel T, Th\u00e9r\u00e9sine M, Andr\u00e8s E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458\u201365. https:\/\/doi.org\/10.1111\/j.1365-2567.2008.03027.x.","journal-title":"Immunology"},{"key":"2648_CR35","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers14174318","volume":"14","author":"Z Pang","year":"2022","unstructured":"Pang Z, Wang Z, Li F, Feng C, Mu X. Current progress of CAR-NK therapy in cancer treatment. Cancers (Basel). 2022;14:4318. https:\/\/doi.org\/10.3390\/cancers14174318.","journal-title":"Cancers (Basel)"},{"key":"2648_CR36","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975.","journal-title":"EBioMedicine"},{"key":"2648_CR37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ccell.2020.03.018","volume":"37","author":"A Karadimitris","year":"2020","unstructured":"Karadimitris A. Cord blood CAR-NK cells: favorable initial efficacy and toxicity but durability of clinical responses not yet clear. Cancer Cell. 2020;37:426\u20137. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.018.","journal-title":"Cancer Cell"},{"key":"2648_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","volume":"7","author":"H Klingemann","year":"2016","unstructured":"Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7:91. https:\/\/doi.org\/10.3389\/fimmu.2016.00091.","journal-title":"Front Immunol"},{"key":"2648_CR39","doi-asserted-by":"publisher","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, et al. Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135. https:\/\/doi.org\/10.3389\/fimmu.2021.732135.","journal-title":"Front Immunol"},{"key":"2648_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/7651_2023_503","volume-title":"Skin stem cells","author":"PP Roudsari","year":"2023","unstructured":"Roudsari PP, Alavi-Moghadam S, Aghayan HR, Arjmand R, Gilany K, Rezaei-Tavirani M, et al. GMP-based isolation of full-term human placenta-derived NK cells for CAR-NK cell therapy in malignant melanoma. In: Turksen K, editor., et al., Skin stem cells. Springer, US: New York; 2023. p. 203\u201313. https:\/\/doi.org\/10.1007\/7651_2023_503. Cited 2025 Aug 19."},{"key":"2648_CR41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-05912-0","volume":"616","author":"SS Santara","year":"2023","unstructured":"Santara SS, Lee DJ, Crespo \u00c2, Hu JJ, Walker C, Ma X, et al. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature. 2023;616:348\u201356. https:\/\/doi.org\/10.1038\/s41586-023-05912-0.","journal-title":"Nature"},{"key":"2648_CR42","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2147\/ITT.S490498","volume":"13","author":"S Chen","year":"2024","unstructured":"Chen S, Yang L, Xia B, Zhu H, Piao Z, Jounaidi Y. A self-activating IL-15 chimeric cytokine receptor to empower cancer immunotherapy. ITT. 2024;13:513\u201324. https:\/\/doi.org\/10.2147\/ITT.S490498.","journal-title":"ITT"},{"key":"2648_CR43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/cancers14030524","volume":"14","author":"E Voynova","year":"2022","unstructured":"Voynova E, Hawk N, Flomerfelt FA, Telford WG, Gress RE, Kanakry JA, et al. Increased activity of a NK-specific CAR-NK framework targeting CD3 and CD5 for T-cell leukemias. Cancers (Basel). 2022;14:524. https:\/\/doi.org\/10.3390\/cancers14030524.","journal-title":"Cancers (Basel)"},{"key":"2648_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13046-025-03351-5","volume":"44","author":"E Yi","year":"2025","unstructured":"Yi E, Lee E, Park HJ, Lee HH, Yun SH, Kim HS. A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells. J Exp Clin Cancer Res. 2025;44:86. https:\/\/doi.org\/10.1186\/s13046-025-03351-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"2648_CR45","doi-asserted-by":"publisher","first-page":"e003894","DOI":"10.1136\/jitc-2021-003894","volume":"9","author":"I Christodoulou","year":"2021","unstructured":"Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer. 2021;9:e003894. https:\/\/doi.org\/10.1136\/jitc-2021-003894.","journal-title":"J Immunother Cancer"},{"key":"2648_CR46","doi-asserted-by":"publisher","first-page":"840844","DOI":"10.3389\/fimmu.2022.840844","volume":"13","author":"X Zhuang","year":"2022","unstructured":"Zhuang X, Long EO. NK cells equipped with a chimeric antigen receptor that overcomes inhibition by HLA class I for adoptive transfer of CAR-NK cells. Front Immunol. 2022;13:840844. https:\/\/doi.org\/10.3389\/fimmu.2022.840844.","journal-title":"Front Immunol"},{"key":"2648_CR47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40164-023-00461-8","volume":"12","author":"Q Ren","year":"2023","unstructured":"Ren Q, Zu Y, Su H, Lu Q, Xiang B, Luo Y, et al. Single VHH-directed BCMA CAR-NK cells for multiple myeloma. Exp Hematol Oncol. 2023;12:98. https:\/\/doi.org\/10.1186\/s40164-023-00461-8.","journal-title":"Exp Hematol Oncol"},{"key":"2648_CR48","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","volume":"14","author":"S Acharya","year":"2024","unstructured":"Acharya S, Basar R, Daher M, Rafei H, Li P, Uprety N, et al. CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK\/CD3\u03b6\/ZAP70 Signaling Axis. Cancer Discov. 2024;14:1879\u2013900. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0096.","journal-title":"Cancer Discov"},{"key":"2648_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-025-00618-7","volume":"14","author":"P Zhang","year":"2025","unstructured":"Zhang P, Feng X, Niu X, Liu Z, Li M, Liu M, et al. CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy. Exp Hematol Oncol. 2025;14:28. https:\/\/doi.org\/10.1186\/s40164-025-00618-7.","journal-title":"Exp Hematol Oncol"},{"key":"2648_CR50","doi-asserted-by":"publisher","first-page":"e13683","DOI":"10.1111\/cpr.13683","volume":"57","author":"Y Wang","year":"2024","unstructured":"Wang Y, Li J, Wang Z, Liu Y, Wang T, Zhang M, et al. Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity. Cell Prolif. 2024;57:e13683. https:\/\/doi.org\/10.1111\/cpr.13683.","journal-title":"Cell Prolif"},{"key":"2648_CR51","doi-asserted-by":"publisher","first-page":"e011887","DOI":"10.1136\/jitc-2025-011887","volume":"13","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zheng X, Wang Z, Xiao Z, Lin Y, Zhang F, et al. CD33KO-CD33-mesothelin loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia. J Immunother Cancer. 2025;13:e011887. https:\/\/doi.org\/10.1136\/jitc-2025-011887.","journal-title":"J Immunother Cancer"},{"key":"2648_CR52","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.14336\/AD.2022.0415","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu R, Luo Q, Luo W, Wan L, Zhu Q, Yin X, et al. A soluble NK-CAR mediates the specific cytotoxicity of NK cells toward the target CD20+ lymphoma cells. Aging Dis. 2022;13:1576\u201388. https:\/\/doi.org\/10.14336\/AD.2022.0415.","journal-title":"Aging Dis"},{"key":"2648_CR53","doi-asserted-by":"publisher","first-page":"e009070","DOI":"10.1136\/jitc-2024-009070","volume":"12","author":"L Co\u00ebnon","year":"2024","unstructured":"Co\u00ebnon L, Rigal E, Courot H, Multrier C, Zemiti S, Lambour J, et al. Generation of non-genetically modified, CAR-like, NK cells. J Immunother Cancer. 2024;12:e009070. https:\/\/doi.org\/10.1136\/jitc-2024-009070.","journal-title":"J Immunother Cancer"},{"key":"2648_CR54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40164-024-00577-5","volume":"13","author":"Y Zu","year":"2024","unstructured":"Zu Y, Ren Q, Zhang J, Su H, Lu Q, Song Y, et al. Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies. Exp Hematol Oncol. 2024;13:104. https:\/\/doi.org\/10.1186\/s40164-024-00577-5.","journal-title":"Exp Hematol Oncol"},{"key":"2648_CR55","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","volume":"11","author":"A Leivas","year":"2021","unstructured":"Leivas A, Valeri A, C\u00f3rdoba L, Garc\u00eda-Ortiz A, Ortiz A, S\u00e1nchez-Vega L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11:146. https:\/\/doi.org\/10.1038\/s41408-021-00537-w.","journal-title":"Blood Cancer J"},{"key":"2648_CR56","doi-asserted-by":"publisher","first-page":"e2122379119","DOI":"10.1073\/pnas.2122379119","volume":"119","author":"H Dong","year":"2022","unstructured":"Dong H, Ham JD, Hu G, Xie G, Vergara J, Liang Y, et al. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022;119:e2122379119. https:\/\/doi.org\/10.1073\/pnas.2122379119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2648_CR57","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12935-023-03153-9","volume":"23","author":"P Klaihmon","year":"2023","unstructured":"Klaihmon P, Luanpitpong S, Kang X, Issaragrisil S. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells. Cancer Cell Int. 2023;23:297. https:\/\/doi.org\/10.1186\/s12935-023-03153-9.","journal-title":"Cancer Cell Int"},{"key":"2648_CR58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","volume":"41","author":"T Flieswasser","year":"2022","unstructured":"Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41:12. https:\/\/doi.org\/10.1186\/s13046-021-02215-y.","journal-title":"J Exp Clin Cancer Res"},{"key":"2648_CR59","doi-asserted-by":"publisher","first-page":"1609840","DOI":"10.3389\/fonc.2025.1609840","volume":"15","author":"R Wu","year":"2025","unstructured":"Wu R, Chen J, Wang G, Han L. CD70 as a target in cancer immunotherapy: advances, challenges, and future directions. Front Oncol. 2025;15:1609840. https:\/\/doi.org\/10.3389\/fonc.2025.1609840.","journal-title":"Front Oncol"},{"key":"2648_CR60","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","volume":"8","author":"S Guo","year":"2024","unstructured":"Guo S, Lei W, Jin X, Liu H, Wang JQ, Deng W, et al. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood Adv. 2024;8:2635\u201345. https:\/\/doi.org\/10.1182\/bloodadvances.2023012202.","journal-title":"Blood Adv"},{"key":"2648_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-024-01604-y","volume":"17","author":"D Sedloev","year":"2024","unstructured":"Sedloev D, Chen Q, Unglaub JM, Schanda N, Hao Y, Besiridou E, et al. Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia. J Hematol Oncol. 2024;17:85. https:\/\/doi.org\/10.1186\/s13045-024-01604-y.","journal-title":"J Hematol Oncol"},{"key":"2648_CR62","doi-asserted-by":"publisher","first-page":"101889","DOI":"10.1016\/j.xcrm.2024.101889","volume":"6","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Y, He X, Mo Z, Zhao M, Liang X, et al. CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell Rep Med. 2025;6:101889. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101889.","journal-title":"Cell Rep Med"},{"key":"2648_CR63","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","volume":"17","author":"A Van den Eynde","year":"2024","unstructured":"Van den Eynde A, Gehrcken L, Verhezen T, Lau HW, Hermans C, Lambrechts H, et al. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. J Hematol Oncol. 2024;17:8. https:\/\/doi.org\/10.1186\/s13045-024-01525-w.","journal-title":"J Hematol Oncol"},{"key":"2648_CR64","doi-asserted-by":"publisher","first-page":"e010763","DOI":"10.1136\/jitc-2024-010763","volume":"13","author":"R Rahnama","year":"2025","unstructured":"Rahnama R, Kizerwetter M, Yang H, Christodoulou I, Guaraca C, Holl NJ, et al. Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality. J Immunother Cancer. 2025;13:e010763. https:\/\/doi.org\/10.1136\/jitc-2024-010763.","journal-title":"J Immunother Cancer"},{"key":"2648_CR65","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199:3360\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1700893.","journal-title":"J Immunol"},{"key":"2648_CR66","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13059-018-1459-4","volume":"19","author":"G Chuai","year":"2018","unstructured":"Chuai G, Ma H, Yan J, Chen M, Hong N, Xue D, et al. DeepCRISPR: optimized CRISPR guide RNA design by deep learning. Genome Biol. 2018;19:80. https:\/\/doi.org\/10.1186\/s13059-018-1459-4.","journal-title":"Genome Biol"},{"key":"2648_CR67","doi-asserted-by":"publisher","first-page":"bbab160","DOI":"10.1093\/bib\/bbab160","volume":"22","author":"G Li","year":"2021","unstructured":"Li G, Iyer B, Prasath VBS, Ni Y, Salomonis N. DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity. Brief Bioinform. 2021;22:bbab160. https:\/\/doi.org\/10.1093\/bib\/bbab160.","journal-title":"Brief Bioinform"},{"key":"2648_CR68","doi-asserted-by":"publisher","first-page":"100251","DOI":"10.1016\/j.cellin.2025.100251","volume":"4","author":"H Tian","year":"2025","unstructured":"Tian H, Li G, Chiu CKC, Li E, Chen Y, Zhu T, et al. Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction. Cell Insight. 2025;4:100251. https:\/\/doi.org\/10.1016\/j.cellin.2025.100251.","journal-title":"Cell Insight"},{"key":"2648_CR69","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","volume":"27","author":"X Wu","year":"2022","unstructured":"Wu X, Matosevic S. Gene-edited and CAR-NK cells: opportunities and challenges with engineering of NK cells for immunotherapy. Mol Ther Oncolytics. 2022;27:224\u201338. https:\/\/doi.org\/10.1016\/j.omto.2022.10.011.","journal-title":"Mol Ther Oncolytics"},{"key":"2648_CR70","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/v13071365","volume":"13","author":"MA Morgan","year":"2021","unstructured":"Morgan MA, Kloos A, Lenz D, Kattre N, Nowak J, Bentele M, et al. Improved activity against acute myeloid leukemia with chimeric antigen receptor (CAR)-NK-92 cells designed to target CD123. Viruses. 2021;13:1365. https:\/\/doi.org\/10.3390\/v13071365.","journal-title":"Viruses"},{"key":"2648_CR71","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","volume":"23","author":"Z Du","year":"2021","unstructured":"Du Z, Ng YY, Zha S, Wang S. piggyBac system to co-express NKG2D CAR and IL-15 to augment the in\u00a0vivo persistence and anti-AML activity of human peripheral blood NK cells. Mol Ther Methods Clin Dev. 2021;23:582\u201396. https:\/\/doi.org\/10.1016\/j.omtm.2021.10.014.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2648_CR72","doi-asserted-by":"publisher","first-page":"847008","DOI":"10.3389\/fimmu.2022.847008","volume":"13","author":"M Soldierer","year":"2022","unstructured":"Soldierer M, Bister A, Haist C, Thivakaran A, Cengiz SC, Sendker S, et al. Genetic engineering and enrichment of human NK cells for CAR-enhanced immunotherapy of hematological malignancies. Front Immunol. 2022;13:847008. https:\/\/doi.org\/10.3389\/fimmu.2022.847008.","journal-title":"Front Immunol"},{"key":"2648_CR73","doi-asserted-by":"publisher","first-page":"1226518","DOI":"10.3389\/fimmu.2023.1226518","volume":"14","author":"RN Silvestre","year":"2023","unstructured":"Silvestre RN, Eitler J, de Azevedo JTC, Tirapelle MC, Fantacini DMC, de Souza LEB, et al. Engineering NK-CAR.19 cells with the IL-15\/IL-15R\u03b1 complex improved proliferation and anti-tumor effect in vivo. Front Immunol. 2023;14:1226518. https:\/\/doi.org\/10.3389\/fimmu.2023.1226518.","journal-title":"Front Immunol"},{"key":"2648_CR74","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1182\/blood-2022-170501","volume":"140","author":"J Reiser","year":"2022","unstructured":"Reiser J, Chan SR, Mathavan K, Sillitti D, Mottershead C, Mattson B, et al. FT555: off-the-shelf CAR-NK cell therapy co-targeting GPRC5D and CD38 for the treatment of multiple myeloma. Blood. 2022;140:4560\u20131. https:\/\/doi.org\/10.1182\/blood-2022-170501.","journal-title":"Blood"},{"key":"2648_CR75","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137:624\u201336. https:\/\/doi.org\/10.1182\/blood.2020007748.","journal-title":"Blood"},{"key":"2648_CR76","doi-asserted-by":"publisher","first-page":"1130442","DOI":"10.3389\/fimmu.2023.1130442","volume":"14","author":"B He","year":"2023","unstructured":"He B, Mai Q, Pang Y, Deng S, He Y, Xue R, et al. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Front Immunol. 2023;14:1130442. https:\/\/doi.org\/10.3389\/fimmu.2023.1130442.","journal-title":"Front Immunol"},{"key":"2648_CR77","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/blood.2020006619","volume":"136","author":"M Gang","year":"2020","unstructured":"Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. 2020;136:2308\u201318. https:\/\/doi.org\/10.1182\/blood.2020006619.","journal-title":"Blood"},{"key":"2648_CR78","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jcyt.2024.06.001","volume":"26","author":"AFB Biggi","year":"2024","unstructured":"Biggi AFB, Silvestre RN, Tirapelle MC, de Azevedo JTC, Garc\u00eda HDM, Henrique Dos Santos M, et al. IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy. Cytotherapy. 2024;26:1320\u201330. https:\/\/doi.org\/10.1016\/j.jcyt.2024.06.001.","journal-title":"Cytotherapy"},{"key":"2648_CR79","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1002\/mco2.553","volume":"5","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Shi Q, Wang P, Huang C, Tang S, Zhou M, et al. iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation. MedComm. 2024;5:e553. https:\/\/doi.org\/10.1002\/mco2.553.","journal-title":"MedComm"},{"key":"2648_CR80","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1182\/bloodadvances.2020001510","volume":"4","author":"X Wang","year":"2020","unstructured":"Wang X, Jasinski DL, Medina JL, Spencer DM, Foster AE, Bayle JH. Inducible MyD88\/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells. Blood Adv. 2020;4:1950\u201364. https:\/\/doi.org\/10.1182\/bloodadvances.2020001510.","journal-title":"Blood Adv"},{"key":"2648_CR81","doi-asserted-by":"publisher","unstructured":"Yi F, Cohen T, Zimmerman N, D\u00fcndar F, Zumbo P, Eltilib R, et al. CAR-engineered lymphocyte persistence is governed by a FAS ligand\/FAS auto-regulatory circuit. bioRxiv. 2024;2024.02.26.582108. https:\/\/doi.org\/10.1101\/2024.02.26.582108.","DOI":"10.1101\/2024.02.26.582108"},{"key":"2648_CR82","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025;405:127\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(24)02462-0.","journal-title":"Lancet"},{"key":"2648_CR83","doi-asserted-by":"publisher","first-page":"7023","DOI":"10.1200\/JCO.2024.42.16_suppl.7023","volume":"42","author":"K Patel","year":"2024","unstructured":"Patel K, Namburi S, Latif T, Oluwole OO, Cross SJ, Simmons G, et al. Interim results from the ELiPSE-1 study: a phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies. JCO. 2024;42:7023\u20137023. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7023.","journal-title":"JCO"},{"key":"2648_CR84","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133:1876\u201387. https:\/\/doi.org\/10.1182\/blood-2018-11-887067.","journal-title":"Blood"},{"key":"2648_CR85","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051\u20137. https:\/\/doi.org\/10.1182\/blood-2004-07-2974.","journal-title":"Blood"},{"key":"2648_CR86","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","volume":"39","author":"F Mo","year":"2021","unstructured":"Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, et al. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021;39:56\u201363. https:\/\/doi.org\/10.1038\/s41587-020-0601-5.","journal-title":"Nat Biotechnol"},{"key":"2648_CR87","doi-asserted-by":"publisher","unstructured":"Williams AM, Hayama KL, Pan Y, Groff B, Mbofung RM, Chang A, et al. Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy. Blood. 2022;140:4547\u20138. https:\/\/doi.org\/10.1182\/blood-2022-167139.","DOI":"10.1182\/blood-2022-167139"},{"key":"2648_CR88","doi-asserted-by":"publisher","first-page":"649710","DOI":"10.3389\/fonc.2021.649710","volume":"11","author":"M Dehbashi","year":"2021","unstructured":"Dehbashi M, Hojati Z, Motovali-Bashi M, Ganjalikhany MR, Cho WC, Shimosaka A, et al. A novel CAR expressing NK cell targeting CD25 with the prospect of overcoming immune escape mechanism in cancers. Front Oncol. 2021;11:649710. https:\/\/doi.org\/10.3389\/fonc.2021.649710.","journal-title":"Front Oncol"},{"key":"2648_CR89","doi-asserted-by":"publisher","first-page":"1275904","DOI":"10.3389\/fimmu.2023.1275904","volume":"14","author":"M Fantini","year":"2023","unstructured":"Fantini M, Arlen PM, Tsang KY. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy. Front Immunol. 2023;14:1275904. https:\/\/doi.org\/10.3389\/fimmu.2023.1275904.","journal-title":"Front Immunol"},{"key":"2648_CR90","doi-asserted-by":"publisher","first-page":"eadd6997","DOI":"10.1126\/sciadv.add6997","volume":"9","author":"L Li","year":"2023","unstructured":"Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, et al. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023;9:eadd6997. https:\/\/doi.org\/10.1126\/sciadv.add6997.","journal-title":"Sci Adv"},{"key":"2648_CR91","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1182\/blood-2022-169758","volume":"140","author":"N Albinger","year":"2022","unstructured":"Albinger N, Bexte T, Buchinger L, Wendel P, Al-Ajami A, Gessner A, et al. CRISPR\/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-CAR-NK cells against AML. Blood. 2022;140:4558\u20139. https:\/\/doi.org\/10.1182\/blood-2022-169758.","journal-title":"Blood"},{"key":"2648_CR92","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15:8439. https:\/\/doi.org\/10.1038\/s41467-024-52388-1.","journal-title":"Nat Commun"},{"key":"2648_CR93","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.3390\/ijms232112828","volume":"23","author":"G Ure\u00f1a-Bail\u00e9n","year":"2022","unstructured":"Ure\u00f1a-Bail\u00e9n G, Dobrowolski JM, Hou Y, Dirlam A, Roig-Merino A, Schleicher S, et al. Preclinical evaluation of CRISPR-edited CAR-NK-92 cells for off-the-shelf treatment of AML and B-ALL. Int J Mol Sci. 2022;23:12828. https:\/\/doi.org\/10.3390\/ijms232112828.","journal-title":"Int J Mol Sci"},{"key":"2648_CR94","doi-asserted-by":"publisher","unstructured":"Wang M, Krueger JB, Gilkey AK, Stelljes EM, Kluesner MG, Pomeroy EJ, et al. Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing. bioRxiv. 2024;2024.03.05.582637. https:\/\/doi.org\/10.1101\/2024.03.05.582637.","DOI":"10.1101\/2024.03.05.582637"},{"key":"2648_CR95","doi-asserted-by":"publisher","first-page":"230","DOI":"10.20517\/jtgg.2023.25","volume":"7","author":"LV Graham","year":"2023","unstructured":"Graham LV, Fisher JG, Khakoo SI, Blunt MD. Targeting KIR as a novel approach to improve CAR-NK cell function. J Transl Genet Genom. 2023;7:230\u20135. https:\/\/doi.org\/10.20517\/jtgg.2023.25.","journal-title":"J Transl Genet Genom"},{"key":"2648_CR96","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","volume":"26","author":"A Rea","year":"2025","unstructured":"Rea A, Santana-Hern\u00e1ndez S, Villanueva J, Sanvicente-Garc\u00eda M, Cabo M, Suarez-Olmos J, et al. Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGF\u03b2 and activin A suppression. Nat Immunol. 2025;26:582\u201394. https:\/\/doi.org\/10.1038\/s41590-025-02103-z.","journal-title":"Nat Immunol"},{"key":"2648_CR97","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3389\/fimmu.2020.02028","volume":"11","author":"A Jamali","year":"2020","unstructured":"Jamali A, Hadjati J, Madjd Z, Mirzaei HR, Thalheimer FB, Agarwal S, et al. Highly efficient generation of transgenically augmented CAR NK cells overexpressing CXCR4. Front Immunol. 2020;11:2028. https:\/\/doi.org\/10.3389\/fimmu.2020.02028.","journal-title":"Front Immunol"},{"key":"2648_CR98","doi-asserted-by":"publisher","first-page":"1383136","DOI":"10.3389\/fimmu.2024.1383136","volume":"15","author":"MW Moles","year":"2024","unstructured":"Moles MW, Erdlei H, Menzel L, Massaro M, Fiori A, Bunse M, et al. CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma. Front Immunol. 2024;15:1383136. https:\/\/doi.org\/10.3389\/fimmu.2024.1383136.","journal-title":"Front Immunol"},{"key":"2648_CR99","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41698-024-00595-w","volume":"8","author":"L Sanz-Ortega","year":"2024","unstructured":"Sanz-Ortega L, Leijonhufvud C, Schoutens L, Lambert M, Levy E, Andersson A, et al. Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity. NPJ Precis Oncol. 2024;8:108. https:\/\/doi.org\/10.1038\/s41698-024-00595-w.","journal-title":"NPJ Precis Oncol"},{"key":"2648_CR100","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","volume":"20","author":"G Roex","year":"2022","unstructured":"Roex G, Campillo-Davo D, Flumens D, Shaw PAG, Krekelbergh L, De Reu H, et al. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. J Transl Med. 2022;20:124. https:\/\/doi.org\/10.1186\/s12967-022-03326-6.","journal-title":"J Transl Med"},{"key":"2648_CR101","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3892\/ol.2023.13822","volume":"25","author":"H Kim","year":"2023","unstructured":"Kim H, Han M, Kim M, Kim H, Im HJ, Kim N, et al. CD19\/CD22 bispecific chimeric antigen receptor\u2011NK\u201192 cells are developed and evaluated. Oncol Lett. 2023;25:236. https:\/\/doi.org\/10.3892\/ol.2023.13822.","journal-title":"Oncol Lett"},{"key":"2648_CR102","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12967-024-04990-6","volume":"22","author":"N Yang","year":"2024","unstructured":"Yang N, Zhang C, Zhang Y, Fan Y, Zhang J, Lin X, et al. CD19\/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. J Transl Med. 2024;22:274. https:\/\/doi.org\/10.1186\/s12967-024-04990-6.","journal-title":"J Transl Med"},{"key":"2648_CR103","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1182\/blood-2022-159289","volume":"140","author":"Z Cao","year":"2022","unstructured":"Cao Z, Yang C, Wang Y, Wang C, Wang Q, Ye G, et al. Allogeneic CAR-NK cell therapy targeting both BCMA and GPRC5D for the treatment of multiple myeloma. Blood. 2022;140:7378\u20137378. https:\/\/doi.org\/10.1182\/blood-2022-159289.","journal-title":"Blood"},{"key":"2648_CR104","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1182\/blood-2022-157453","volume":"140","author":"B Garrison","year":"2022","unstructured":"Garrison B, Deng H, Yucel G, Frankel NW, Gordley R, Hung M, et al. Senti-202, a selective, off-the-shelf, preclinical CAR-NK cell therapy with CD33 and\/or FLT3 activating CAR, healthy cell protection from endomucin (EMCN) inhibitory CAR and calibrated release IL-15 for hematologic malignancies including AML. Blood. 2022;140:4531\u20132. https:\/\/doi.org\/10.1182\/blood-2022-157453.","journal-title":"Blood"},{"key":"2648_CR105","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ymthe.2021.11.013","volume":"30","author":"F Fei","year":"2022","unstructured":"Fei F, Rong L, Jiang N, Wayne AS, Xie J. Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor. Mol Ther. 2022;30:1215\u201326. https:\/\/doi.org\/10.1016\/j.ymthe.2021.11.013.","journal-title":"Mol Ther"},{"key":"2648_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5562630","volume":"2021","author":"S Luanpitpong","year":"2021","unstructured":"Luanpitpong S, Poohadsuan J, Klaihmon P, Issaragrisil S, Xu B. Selective cytotoxicity of single and dual anti-CD19 and anti-CD138 chimeric antigen receptor-natural killer cells against hematologic malignancies. J Immunol Res. 2021;2021:1\u201316. https:\/\/doi.org\/10.1155\/2021\/5562630.","journal-title":"J Immunol Res"},{"key":"2648_CR107","doi-asserted-by":"publisher","first-page":"10288","DOI":"10.1182\/blood-2022-168981","volume":"140","author":"Z Davis","year":"2022","unstructured":"Davis Z, Cichocki F, Felices M, Wang H, Hinderlie P, Juckett M, et al. A novel dual-antigen targeting approach enables off-the-shelf CAR NK cells to effectively recognize and eliminate the heterogenous population associated with AML. Blood. 2022;140:10288\u20139. https:\/\/doi.org\/10.1182\/blood-2022-168981.","journal-title":"Blood"},{"key":"2648_CR108","doi-asserted-by":"publisher","first-page":"e2205449","DOI":"10.1002\/advs.202205449","volume":"10","author":"X Yang","year":"2023","unstructured":"Yang X, Bian J, Wang Z, He M, Yang Y, Li Q, et al. A bio-liposome activating natural killer cell by illuminating tumor homogenization antigen properties. Adv Sci (Weinh). 2023;10:e2205449. https:\/\/doi.org\/10.1002\/advs.202205449.","journal-title":"Adv Sci (Weinh)"},{"key":"2648_CR109","doi-asserted-by":"publisher","first-page":"216103","DOI":"10.1016\/j.canlet.2023.216103","volume":"558","author":"R Zhang","year":"2023","unstructured":"Zhang R, Liu Q, Zhou S, He H, Zhao M, Ma W. Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia. Cancer Lett. 2023;558:216103. https:\/\/doi.org\/10.1016\/j.canlet.2023.216103.","journal-title":"Cancer Lett"},{"key":"2648_CR110","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.3390\/cells12232748","volume":"12","author":"B Motais","year":"2023","unstructured":"Motais B, Charv\u00e1tov\u00e1 S, Walek Z, H\u00e1jek R, Bag\u00f3 JR. NK92 expressing anti-BCMA CAR and secreted TRAIL for the treatment of multiple myeloma: preliminary in vitro assessment. Cells. 2023;12:2748. https:\/\/doi.org\/10.3390\/cells12232748.","journal-title":"Cells"},{"key":"2648_CR111","doi-asserted-by":"publisher","first-page":"e2207394","DOI":"10.1002\/advs.202207394","volume":"10","author":"C Liao","year":"2023","unstructured":"Liao C, Wang Y, Huang Y, Duan Y, Liang Y, Chen J, et al. CD38-specific CAR integrated into CD38 locus driven by different promoters causes distinct antitumor activities of T and NK cells. Adv Sci (Weinh). 2023;10:e2207394. https:\/\/doi.org\/10.1002\/advs.202207394.","journal-title":"Adv Sci (Weinh)"},{"key":"2648_CR112","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/blood-2022-166994","volume":"140","author":"B Dhakal","year":"2022","unstructured":"Dhakal B, Berdeja JG, Gregory T, Ly T, Bickers C, Zong X, et al. Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma. Blood. 2022;140:4586\u20137. https:\/\/doi.org\/10.1182\/blood-2022-166994.","journal-title":"Blood"},{"key":"2648_CR113","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2020.271908","volume":"107","author":"M Gurney","year":"2022","unstructured":"Gurney M, Stikvoort A, Nolan E, Kirkham-McCarthy L, Khoruzhenko S, Shivakumar R, et al. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. Haematologica. 2022;107:437\u201345. https:\/\/doi.org\/10.3324\/haematol.2020.271908.","journal-title":"Haematologica"},{"key":"2648_CR114","doi-asserted-by":"publisher","first-page":"17231","DOI":"10.3390\/ijms242417231","volume":"24","author":"A Edri","year":"2023","unstructured":"Edri A, Ben-Haim N, Hailu A, Brycman N, Berhani-Zipori O, Rifman J, et al. Nicotinamide-expanded allogeneic natural killer cells with CD38 deletion, expressing an enhanced CD38 chimeric antigen receptor, target multiple myeloma cells. Int J Mol Sci. 2023;24:17231. https:\/\/doi.org\/10.3390\/ijms242417231.","journal-title":"Int J Mol Sci"},{"key":"2648_CR115","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s41375-023-01948-3","volume":"37","author":"J Jiang","year":"2023","unstructured":"Jiang J, Chen J, Liao C, Duan Y, Wang Y, Shang K, et al. Inserting EF1\u03b1-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia. 2023;37:1660\u201370. https:\/\/doi.org\/10.1038\/s41375-023-01948-3.","journal-title":"Leukemia"},{"key":"2648_CR116","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jcyt.2023.03.006","volume":"25","author":"M Karvouni","year":"2023","unstructured":"Karvouni M, Vidal-Manrique M, Susek KH, Hussain A, Gilljam M, Zhang Y, et al. Challenges in \u03b1CD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide. Cytotherapy. 2023;25:763\u201372. https:\/\/doi.org\/10.1016\/j.jcyt.2023.03.006.","journal-title":"Cytotherapy"},{"key":"2648_CR117","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","volume":"28","author":"Y Li","year":"2022","unstructured":"Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022;28:2133\u201344. https:\/\/doi.org\/10.1038\/s41591-022-02003-x.","journal-title":"Nat Med"},{"key":"2648_CR118","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.stem.2024.06.011","volume":"31","author":"Q Hammer","year":"2024","unstructured":"Hammer Q, Perica K, Mbofung RM, van Ooijen H, Martin KE, Momayyezi P, et al. Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell Stem Cell. 2024;31:1376-1386.e8. https:\/\/doi.org\/10.1016\/j.stem.2024.06.011.","journal-title":"Cell Stem Cell"},{"key":"2648_CR119","doi-asserted-by":"publisher","first-page":"1504459","DOI":"10.3389\/fimmu.2024.1504459","volume":"15","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Xia C, Weng Q, Zhang L, Wang Y, Liu Y, et al. Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals. Front Immunol. 2024;15:1504459. https:\/\/doi.org\/10.3389\/fimmu.2024.1504459.","journal-title":"Front Immunol"},{"key":"2648_CR120","doi-asserted-by":"publisher","first-page":"200885","DOI":"10.1016\/j.omton.2024.200885","volume":"32","author":"D Kwon","year":"2024","unstructured":"Kwon D, Moon BK, Han M, Lee TW, Lee J, Kang KS. Genetically stable multi-gene edited iPSCs-derived NK cells for enhanced cancer immunotherapy. Mol Ther Oncol. 2024;32:200885. https:\/\/doi.org\/10.1016\/j.omton.2024.200885.","journal-title":"Mol Ther Oncol"},{"key":"2648_CR121","doi-asserted-by":"publisher","first-page":"12755","DOI":"10.1038\/s41598-025-97584-1","volume":"15","author":"A Moazzeni","year":"2025","unstructured":"Moazzeni A, Kheirandish M, Khamisipour G, Rahbarizadeh F, Pourfathollah AA. Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy. Sci Rep. 2025;15:12755. https:\/\/doi.org\/10.1038\/s41598-025-97584-1.","journal-title":"Sci Rep"},{"key":"2648_CR122","doi-asserted-by":"publisher","first-page":"1225549","DOI":"10.3389\/fimmu.2023.1225549","volume":"14","author":"S Martin-Iglesias","year":"2023","unstructured":"Martin-Iglesias S, Herrera L, Santos S, Vesga M\u00c1, Eguizabal C, Lanceros-Mendez S, et al. Analysis of the impact of handling and culture on the expansion and functionality of NK cells. Front Immunol. 2023;14:1225549. https:\/\/doi.org\/10.3389\/fimmu.2023.1225549.","journal-title":"Front Immunol"},{"key":"2648_CR123","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.1039\/d2lc00798c","volume":"22","author":"DN Philpott","year":"2022","unstructured":"Philpott DN, Chen K, Atwal RS, Li D, Christie J, Sargent EH, et al. Ultrathroughput immunomagnetic cell sorting platform. Lab Chip. 2022;22:4822\u201330. https:\/\/doi.org\/10.1039\/d2lc00798c.","journal-title":"Lab Chip"},{"key":"2648_CR124","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1039\/d0lc00158a","volume":"20","author":"S Sarkar","year":"2020","unstructured":"Sarkar S, Kang W, Jiang S, Li K, Ray S, Luther E, et al. Machine learning-aided quantification of antibody-based cancer immunotherapy by natural killer cells in microfluidic droplets. Lab Chip. 2020;20:2317\u201327. https:\/\/doi.org\/10.1039\/d0lc00158a.","journal-title":"Lab Chip"},{"key":"2648_CR125","doi-asserted-by":"publisher","first-page":"e008912","DOI":"10.1136\/jitc-2024-008912","volume":"12","author":"MR Sullivan","year":"2024","unstructured":"Sullivan MR, Finocchiaro M, Yang Y, Thomas J, Ali A, Kaplan I, et al. An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cells. J Immunother Cancer. 2024;12:e008912. https:\/\/doi.org\/10.1136\/jitc-2024-008912.","journal-title":"J Immunother Cancer"},{"key":"2648_CR126","doi-asserted-by":"publisher","first-page":"113916","DOI":"10.1016\/j.bios.2021.113916","volume":"200","author":"R Zenhausern","year":"2022","unstructured":"Zenhausern R, Day AS, Safavinia B, Han S, Rudy PE, Won YW, et al. Natural killer cell detection, quantification, and subpopulation identification on paper microfluidic cell chromatography using smartphone-based machine learning classification. Biosens Bioelectron. 2022;200:113916. https:\/\/doi.org\/10.1016\/j.bios.2021.113916.","journal-title":"Biosens Bioelectron"},{"key":"2648_CR127","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/ITT.S503984","volume":"14","author":"S Luanpitpong","year":"2025","unstructured":"Luanpitpong S, Janan M, Poohadsuan J, Rodboon N, Samart P, Rungarunlert S, et al. A high-throughput, three-dimensional multiple myeloma model recapitulating tumor-stroma interactions for CAR-immune cell-mediated cytotoxicity assay. Immunotargets Ther. 2025;14:321\u201338. https:\/\/doi.org\/10.2147\/ITT.S503984.","journal-title":"Immunotargets Ther"},{"key":"2648_CR128","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.omtm.2020.06.014","volume":"18","author":"Y Yang","year":"2020","unstructured":"Yang Y, Badeti S, Tseng HC, Ma MT, Liu T, Jiang JG, et al. Superior expansion and cytotoxicity of human primary NK and CAR-NK cells from various sources via enriched metabolic pathways. Mol Ther Methods Clin Dev. 2020;18:428\u201345. https:\/\/doi.org\/10.1016\/j.omtm.2020.06.014.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2648_CR129","doi-asserted-by":"publisher","DOI":"10.3791\/62336","author":"M Ma","year":"2022","unstructured":"Ma M, Badeti S, Kim JK, Liu D. Natural Killer (NK) and CAR-NK cell expansion method using membrane bound-IL-21-modified B cell line. J Vis Exp. 2022. https:\/\/doi.org\/10.3791\/62336.","journal-title":"J Vis Exp"},{"key":"2648_CR130","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.21873\/anticanres.16577","volume":"43","author":"DY Lee","year":"2023","unstructured":"Lee DY, Kim Y, Park JS, Choi JU, Jeong HG, Park CH. Development of genetically engineered feeder cells for natural killer cell expansion. Anticancer Res. 2023;43:3897\u2013904. https:\/\/doi.org\/10.21873\/anticanres.16577.","journal-title":"Anticancer Res"},{"key":"2648_CR131","doi-asserted-by":"publisher","first-page":"626098","DOI":"10.3389\/fimmu.2021.626098","volume":"12","author":"E Liu","year":"2021","unstructured":"Liu E, Ang SOT, Kerbauy L, Basar R, Kaur I, Kaplan M, et al. GMP-compliant universal antigen presenting cells (uAPC) promote the metabolic fitness and antitumor activity of armored cord blood CAR-NK cells. Front Immunol. 2021;12:626098. https:\/\/doi.org\/10.3389\/fimmu.2021.626098.","journal-title":"Front Immunol"},{"key":"2648_CR132","doi-asserted-by":"publisher","first-page":"119960","DOI":"10.1016\/j.biomaterials.2020.119960","volume":"247","author":"YH Ahn","year":"2020","unstructured":"Ahn YH, Ren L, Kim SM, Seo SH, Jung CR, Kim DS, et al. A three-dimensional hyaluronic acid-based niche enhances the therapeutic efficacy of human natural killer cell-based cancer immunotherapy. Biomaterials. 2020;247:119960. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.119960.","journal-title":"Biomaterials"},{"key":"2648_CR133","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41409-023-02180-4","volume":"59","author":"N Albinger","year":"2024","unstructured":"Albinger N, M\u00fcller S, Kostyra J, Kuska J, Mertlitz S, Penack O, et al. Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia. Bone Marrow Transplant. 2024;59:489\u201395. https:\/\/doi.org\/10.1038\/s41409-023-02180-4.","journal-title":"Bone Marrow Transplant"},{"key":"2648_CR134","doi-asserted-by":"publisher","first-page":"1412378","DOI":"10.3389\/fimmu.2024.1412378","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Byrne ME, Liu C, Ma MT, Liu D. Scalable process development of NK and CAR-NK expansion in a closed bioreactor. Front Immunol. 2024;15:1412378. https:\/\/doi.org\/10.3389\/fimmu.2024.1412378.","journal-title":"Front Immunol"},{"key":"2648_CR135","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13287-023-03461-x","volume":"14","author":"W Wen","year":"2023","unstructured":"Wen W, Chen X, Shen XY, Li HY, Zhang F, Fang F-Q, et al. Enhancing cord blood stem cell-derived NK cell growth and differentiation through hyperosmosis. Stem Cell Res Ther. 2023;14:295. https:\/\/doi.org\/10.1186\/s13287-023-03461-x.","journal-title":"Stem Cell Res Ther"},{"key":"2648_CR136","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jcyt.2024.10.006","volume":"27","author":"H Lin","year":"2025","unstructured":"Lin H, Ye S, Zhang S, Ge T, Li D, Huang L, et al. Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy. Cytotherapy. 2025;27:247\u201357. https:\/\/doi.org\/10.1016\/j.jcyt.2024.10.006.","journal-title":"Cytotherapy"},{"key":"2648_CR137","doi-asserted-by":"publisher","first-page":"e70040","DOI":"10.1002\/cpz1.70040","volume":"4","author":"T Ingegnere","year":"2024","unstructured":"Ingegnere T, Segain B, Cozzani A, Carlsten M, Mitra S, Gaggero S. Optimizing CAR-NK cell transduction and expansion: leveraging cytokine modulation for enhanced performance. Current Protocols. 2024;4:e70040. https:\/\/doi.org\/10.1002\/cpz1.70040.","journal-title":"Current Protocols"},{"key":"2648_CR138","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jcyt.2021.04.010","volume":"23","author":"P Chockley","year":"2021","unstructured":"Chockley P, Patil SL, Gottschalk S. Transient blockade of TBK1\/IKK\u03b5 allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors. Cytotherapy. 2021;23:787\u201392. https:\/\/doi.org\/10.1016\/j.jcyt.2021.04.010.","journal-title":"Cytotherapy"},{"key":"2648_CR139","doi-asserted-by":"publisher","first-page":"e1507","DOI":"10.1002\/cti2.1507","volume":"13","author":"A Pfefferle","year":"2024","unstructured":"Pfefferle A, Contet J, Wong K, Chen C, Verhoeyen E, Slichter CK, et al. Optimisation of a primary human CAR-NK cell manufacturing pipeline. Clin Transl Immunology. 2024;13:e1507. https:\/\/doi.org\/10.1002\/cti2.1507.","journal-title":"Clin Transl Immunology"},{"key":"2648_CR140","doi-asserted-by":"publisher","first-page":"e2412544","DOI":"10.1002\/advs.202412544","volume":"12","author":"H Kim","year":"2025","unstructured":"Kim H, Lee M, Han B, Kim J, Cho D, Doh J, et al. Advancing allogeneic NK cell immunotherapy through microfluidic gene delivery. Adv Sci (Weinh). 2025;12:e2412544. https:\/\/doi.org\/10.1002\/advs.202412544.","journal-title":"Adv Sci (Weinh)"},{"key":"2648_CR141","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40259-021-00494-7","volume":"35","author":"X Yao","year":"2021","unstructured":"Yao X, Matosevic S. Cryopreservation of NK and T cells without DMSO for adoptive cell-based immunotherapy. BioDrugs. 2021;35:529\u201345. https:\/\/doi.org\/10.1007\/s40259-021-00494-7.","journal-title":"BioDrugs"},{"key":"2648_CR142","doi-asserted-by":"publisher","first-page":"104835","DOI":"10.1016\/j.cryobiol.2023.104835","volume":"114","author":"R Xu","year":"2024","unstructured":"Xu R, Shi X, Huang H, Tan WS, Cai H. Development of a Me2SO-free cryopreservation medium and its long-term cryoprotection on the CAR-NK cells. Cryobiology. 2024;114:104835. https:\/\/doi.org\/10.1016\/j.cryobiol.2023.104835.","journal-title":"Cryobiology"},{"key":"2648_CR143","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.intimp.2012.09.014","volume":"14","author":"X Deng","year":"2012","unstructured":"Deng X, Terunuma H, Nieda M, Xiao W, Nicol A. Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells. Int Immunopharmacol. 2012;14:593\u2013605. https:\/\/doi.org\/10.1016\/j.intimp.2012.09.014.","journal-title":"Int Immunopharmacol"},{"key":"2648_CR144","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood-2021-151185","volume":"138","author":"V Bachanova","year":"2021","unstructured":"Bachanova V, Ghobadi A, Patel K, Park JH, Flinn IW, Shah P, et al. Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed\/refractory B-cell lymphoma. Blood. 2021;138:823\u2013823. https:\/\/doi.org\/10.1182\/blood-2021-151185.","journal-title":"Blood"},{"key":"2648_CR145","doi-asserted-by":"publisher","first-page":"10327","DOI":"10.1182\/blood-2022-166728","volume":"140","author":"M Juckett","year":"2022","unstructured":"Juckett M, Mailankody S, Eghtedar A, Bickers C, Zong X, Wong L, et al. A phase I study of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy in combination with daratumumab in relapsed\/refractory multiple myeloma. Blood. 2022;140:10327\u20138. https:\/\/doi.org\/10.1182\/blood-2022-166728.","journal-title":"Blood"},{"key":"2648_CR146","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","volume":"37","author":"A Alarcon Tomas","year":"2023","unstructured":"Alarcon Tomas A, Fein JA, Fried S, Flynn JR, Devlin SM, Fingrut WB, et al. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia. 2023;37:154\u201363. https:\/\/doi.org\/10.1038\/s41375-022-01739-2.","journal-title":"Leukemia"},{"key":"2648_CR147","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1007\/s00432-023-04575-8","volume":"149","author":"LR Soldi","year":"2023","unstructured":"Soldi LR, Silva VLC, Rabelo DH, Uehara IA, Silva MJB. Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms. J Cancer Res Clin Oncol. 2023;149:6661\u201373. https:\/\/doi.org\/10.1007\/s00432-023-04575-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2648_CR148","doi-asserted-by":"publisher","first-page":"1533044","DOI":"10.3389\/fimmu.2025.1533044","volume":"16","author":"DH Jo","year":"2025","unstructured":"Jo DH, Kaczmarek S, Khan AUH, Pervin J, Clark DM, Gadde S, et al. Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression. Front Immunol. 2025;16:1533044. https:\/\/doi.org\/10.3389\/fimmu.2025.1533044.","journal-title":"Front Immunol"},{"key":"2648_CR149","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-15-0304","volume":"21","author":"DM Benson","year":"2015","unstructured":"Benson DM, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, et al. A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed\/refractory multiple myeloma. Clin Cancer Res. 2015;21:4055\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0304.","journal-title":"Clin Cancer Res"},{"key":"2648_CR150","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","volume":"71","author":"G Zhao","year":"2022","unstructured":"Zhao G, Wei R, Feng L, Wu Y, He F, Xiao M, et al. Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature. Cancer Immunol Immunother. 2022;71:39\u201344. https:\/\/doi.org\/10.1007\/s00262-021-02959-8.","journal-title":"Cancer Immunol Immunother"},{"key":"2648_CR151","doi-asserted-by":"crossref","unstructured":"Zhang L, Jin G, Chen Z, Yu C, Li Y, Li Y, et al. Lenalidomide improves the antitumor activity of CAR-T cells directed toward the intracellular Wilms Tumor 1 antigen. In: Hematology. Taylor & Francis; 2021. https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/16078454.2021.1981534. Accessed 24 Oct 2025. Cited 2025 Oct 24.","DOI":"10.1080\/16078454.2021.1981534"},{"key":"2648_CR152","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:1083\u20139.","journal-title":"Am J Cancer Res"},{"key":"2648_CR153","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei W, Liu H, Deng W, Chen W, Liang Y, Gao W, et al. Safety and feasibility of 4\u20131BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial. Nat Cancer. 2025;6:786\u2013800. https:\/\/doi.org\/10.1038\/s43018-025-00940-3.","journal-title":"Nat Cancer"},{"key":"2648_CR154","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1910607.","journal-title":"N Engl J Med"},{"key":"2648_CR155","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30:772\u201384. https:\/\/doi.org\/10.1038\/s41591-023-02785-8.","journal-title":"Nat Med"},{"key":"2648_CR156","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1182\/blood-2024-194807","volume":"144","author":"JM Darrah","year":"2024","unstructured":"Darrah JM, Varadarajan I, Mehta A, Saultz JN, McKinney M, Ghosh M, et al. Efficacy and safety of TAK-007, cord blood-derived CD19 CAR-NK cells, in adult patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL). Blood. 2024;144:95\u201395. https:\/\/doi.org\/10.1182\/blood-2024-194807.","journal-title":"Blood"},{"key":"2648_CR157","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1182\/blood-2023-173582","volume":"142","author":"CS Sauter","year":"2023","unstructured":"Sauter CS, Borthakur G, Mountjoy L, Rotta M, Liu H, Murthy HS, et al. A phase 1 study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapy, with fludarabine and cytarabine in patients with acute myeloid leukemia. Blood. 2023;142:2097\u20132097. https:\/\/doi.org\/10.1182\/blood-2023-173582.","journal-title":"Blood"},{"key":"2648_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang R, Wang X, Yan H, Tan X, Ma Y, Wang M, et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial. Exp Hematol Oncol. 2025;14:1. https:\/\/doi.org\/10.1186\/s40164-024-00592-6.","journal-title":"Exp Hematol Oncol"},{"key":"2648_CR159","unstructured":"Senti bio determines Recommended Phase 2 Dose (RP2D) in phase 1 study of SENTI-202 for the treatment of relapsed\/refractory hematologic malignancies, including acute myeloid leukemia. Senti Biosciences, Inc. https:\/\/investors.sentibio.com\/news-releases\/news-release-details\/senti-bio-determines-recommended-phase-2-dose-rp2d-phase-1-study\/. Accessed 23 Sept 2025. Cited 2025 Sept 23."},{"key":"2648_CR160","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13287-023-03272-0","volume":"14","author":"J Yuan","year":"2023","unstructured":"Yuan J, Wang F, Ren H. Intrathecal CAR-NK cells infusion for isolated CNS relapse after allogeneic stem cell transplantation: case report. Stem Cell Res Ther. 2023;14:44. https:\/\/doi.org\/10.1186\/s13287-023-03272-0.","journal-title":"Stem Cell Res Ther"},{"key":"2648_CR161","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13:86. https:\/\/doi.org\/10.1186\/s13045-020-00910-5.","journal-title":"J Hematol Oncol"},{"key":"2648_CR162","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40164-024-00522-6","volume":"13","author":"L Egli","year":"2024","unstructured":"Egli L, Kaulfuss M, Mietz J, Picozzi A, Verhoeyen E, M\u00fcnz C, et al. CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison. Exp Hematol Oncol. 2024;13:51. https:\/\/doi.org\/10.1186\/s40164-024-00522-6.","journal-title":"Exp Hematol Oncol"},{"key":"2648_CR163","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, et al. Cytokine-mediated CAR T therapy resistance in AML. Nat Med. 2024;30:3697\u2013708. https:\/\/doi.org\/10.1038\/s41591-024-03271-5.","journal-title":"Nat Med"},{"key":"2648_CR164","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.3390\/ijms22115899","volume":"22","author":"E Wrona","year":"2021","unstructured":"Wrona E, Borowiec M, Potemski P. CAR-NK cells in the treatment of solid tumors. IJMS. 2021;22:5899. https:\/\/doi.org\/10.3390\/ijms22115899.","journal-title":"IJMS"},{"key":"2648_CR165","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/1521-4141(200001)30:1<59::AID-IMMU59>3.0.CO;2-1","volume":"30","author":"M Delespine-Carmagnat","year":"2000","unstructured":"Delespine-Carmagnat M, Bouvier G, Bertoglio J. Association of STAT1, STAT3 and STAT5 proteins with the IL-2 receptor involves different subdomains of the IL-2 receptor beta chain. Eur J Immunol. 2000;30:59\u201368. https:\/\/doi.org\/10.1002\/1521-4141(200001)30:1%253C59::AID-IMMU59%253E3.0.CO;2-1.","journal-title":"Eur J Immunol"},{"key":"2648_CR166","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.0105-2896.2004.00203.x","volume":"202","author":"PE Kovanen","year":"2004","unstructured":"Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev. 2004;202:67\u201383. https:\/\/doi.org\/10.1111\/j.0105-2896.2004.00203.x.","journal-title":"Immunol Rev"},{"key":"2648_CR167","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJM198704093161501","volume":"316","author":"SA Rosenberg","year":"1987","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889\u201397. https:\/\/doi.org\/10.1056\/NEJM198704093161501.","journal-title":"N Engl J Med"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02648-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:16:18Z","timestamp":1777940178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02648-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":167,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2648"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02648-z","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}